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Hepatitis B virus (HBV) infection and its compli­
cations cause substantial medical and financial 
burdens to the healthcare system, and have become 
a major global public health concern.[1] A global 
estimate is that 240 million individuals are chronically 
infected with HBV.[2] South Africa (SA) had an estimated 10% 
prevalence of HBV in the prevaccination era, with a significant 
reduc tion after the introduction of neonatal vaccination in 1995, as 
shown in recent studies.[3] The prevalence of chronic carriage of HBV 
in SA blacks is estimated to be 5 ­ 16% in rural males, 8 ­ 9% in urban 
males, 4 ­ 12% in rural females and 2.7 ­ 4% in urban females.[4]
Despite enormous strides in preventing HBV infection, perinatal 
transmission continues to contribute significantly to HBV epi­
demiology worldwide and could account for approximately 50% 
of chronically infected individuals.[1] The horizontal route of 
transmission has been reported to be the predominant mode of HBV 
transmission in SA,[4,5] despite numerous African studies that have 
reported that perinatal vertical transmission occurs in 2 ­ 30% of 
infants born to HBV­infected mothers.[6­8] 
In the absence of immunoprophylaxis, perinatal transmission 
occurs in 10 ­ 20% of women who are seropositive for hepatitis B 
surface antigen (HBsAg) but seronegative for hepatitis e antigen 
(HBeAg), and up to 90% of perinatal transmission occurs in women 
who are seropositive for both HBsAg and HBeAg.[9] HBeAg is a 
surrogate marker of high HBV viral load, as it is positive during the 
high replicative phase of HBV.[9] The risk of progression of acute 
to chronic HBV infection is inversely proportional to the age at 
which the infection was acquired. HBV infection is associated with 
a partial immune tolerance in infected infants and therefore results 
in a 95% chance of chronicity, compared with 30% in children aged 
1 ­ 5 years and <5% in adults.[10] Chronic hepatitis B sequelae include 
cirrhosis, hepatic carcinoma, glomerulonephritis and end­stage 
renal disease in children.[11] Risk factors known to predispose to 
perinatal transmission include maternal HBeAg positivity, HBsAg 
titre, detectable HBV DNA, acute hepatitis B acquired in pregnancy, 
a history of threatened preterm labour and specific allelic mutations 
in maternal HBV.[12] The risk of vertical transmission is higher during 
the intrapartum period (at or near the time of birth) and is reported to 
result from exposure of the neonate to maternal blood and secretions 
during delivery. Intrauterine transmission of HBV is rare, accounting 
for <5% of infants born to HbeAg­ and HBsAg­positive mothers. It is 
understood to result from transplacental leakage of HBeAg­positive 
maternal blood during uterine contractions in pregnancy, and also 
from the disruption of placental membranes.[9,13]
Antenatal screening and administration of the birth­dose HBV 
vaccine and immunoglobulins are known to be 95% effective in 
reducing vertical transmission of HBV.[11,14] In SA, universal maternal 
antenatal screening is not practised in the public sector. The HBV 
immunisation schedule in SA introduced in 1995 initiates HBV 
vaccination at 6 weeks of age, with subsequent doses at 10 and 14 weeks. 
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administration of HBV vaccine at birth is needed for prevention of vertical transmission. 
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Sub­Saharan Africa is also highly endemic for 
HIV/AIDS, which shares a common route 
of transmission with HBV.[15,16] Local studies 
have shown a higher HBV prevalence in HIV 
co­infected individuals compared with their 
HIV­uninfected counterparts.[17,18]
Objective
To assess the need for HBV screening in 
antenatal clinics in the era of HIV/AIDS.
Methods
This was a retrospective study conducted at 
the antenatal clinic of 1 Military Hospital in 
Tshwane, which offered universal hepatitis B 
antenatal screening and HIV testing to pat­
ients attending its antenatal clinic. During 
the study period (2008 ­ 2013), a total of 
2  513 patients’ results were retrieved in the 
laboratory information system (LIS) for 
the antenatal clinic of 1 Military Hospital, 
Tshwane, SA. Of these patients, 2 368 were 
enrolled in this study as they had both HIV 
and HBV results. Those who did not have 
both results were excluded (Fig. 1). Laboratory 
data for the period of January 2008 to 
December 2013 were retrieved from the LIS 
and results for HBV (HBsAg, HBeAg), HIV 
and CD4 count were collected and analysed. 
Axsym immunoassays (Abbott Diagnostics, 
Germany) were used for HBV and HIV 
serology, after which HIV confirmation was 
done on Vironostika HIV assay (bioMérieux, 
USA). Rapid HIV tests were also used for HIV 
diagnosis. Demographic data such as patient 
age were also retrieved. Ethical approval 
was received from the ethics committees of 
1 Military Hospital and the University of 
Pretoria (6/2013).
Data analysis
Descriptive statistics consisting of summary 
statistics (i.e. mean, range) for numerical 
data and frequencies for categorical data 
were used. Comparison between the groups 
was done using a two­sample t­test for 
propor tions. The software used was Stata 13 
(StataCorp, USA). A p­value of <0.05 was 
considered statistically significant.
Results
The mean age of the participants was 29 
years (range 14 ­ 46). Twenty­seven patients’ 
results were in the under­18 years category, 
and none of them was HBsAg­positive 
(Table 1). HIV prevalence in the whole 
group was 20.5% (95% confidence interval 
(CI) 0.189 ­ 0.222). The median CD4 count 
was 522 cells/μL (interquartile range 370 ­ 
711) in the HIV­infected women. There was 
an overall HBV prevalence of 0.8% (95% 
CI 0.005 ­ 0.011). The HBsAg prevalence 
was significantly higher (2.1%) in the 
HIV co­infected as opposed to the HIV­
uninfected (0.4%) patients (p=0.0001) (Table 
2). HBeAg positivity was 30.0% (3/10) in the 
HIV co­infected as opposed to 37.5% (3/8) 
in the HIV­uninfected women (p=0.7400) 
(Table 3).
Discussion
This study evaluated the value of screening 
for HBV in antenatal clinics in the era of 
HIV/AIDS. The HIV prevalence of 20.5% 
in this study is lower than the 2012 HIV 
prevalence estimate of 29.9% in Gauteng’s 
antenatal clinics.[19] The absence of HBsAg 
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Fig. 1. Algorithm showing how patients were enrolled into this study. Only those who had both HIV and 
HBV results were enrolled.
Table 1. Age distribution of patients and 
HBsAg prevalence
Age 
(years)
HBV-
positive 
HBV-
negative Total
≤18 0 27 27
19 ­ 24 3 558 561
25 ­ 29 3 690 693
30 ­ 34 7 592 599
≥35 5 483 488
Total 18 2 350 2 368
Table 2. HBsAg prevalence among HIV-infected v. HIV-uninfected patients
HIV-infected 
(N=486)
HIV-uninfected 
(N=1 882) p-value
HbsAg­positive, n (%)  
(95% CI)
10 (2.1) 
(0.008 ­ 0.034)
8 (0.4)
(0.001 ­ 0.007) 
0.0001
Table 3. HBeAg prevalence among HIV-infected v. HIV-uninfected patients
HIV-infected (N=10) HIV-uninfected (N=8) p-value
HBeAg­positive, n (%)  
(95% CI)
3 (30.0)
(0.016 ­ 0.584)
3 (37.5)
(0.395 ­ 0.710)
0.7400
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positivity in the under­18 age group in this study (Table 1) is 
suggestive of HBV prevention from vaccination, as these patients 
probably received HBV vaccination (introduced in SA in 1995) in 
childhood. It was not surprising to see that HBV prevalence was 
fivefold higher in HIV­infected as opposed to HIV­uninfected 
pregnant women (Table 2). This finding has been reported in other 
SA studies.[17,18] A study in pregnant women in KwaZulu­Natal (KZN) 
revealed a 7.4% HBV prevalence in HBV­HIV co­infected patients.[20] 
A study conducted on pregnant women delivering in a rural hospital 
in Malawi in 1998 reported that 8% of pregnant women had HBV­
HIV co­infection.[21] The low co­infection rate of 2.1% in this study 
could be due to higher CD4 counts (median 522 cells/μL) in this 
study group as opposed to the median of 328 in the KZN study and 
the fact that it was conducted in a low HBV prevalence area of SA (i.e. 
an urban setting in Gauteng Province).[17]
Currently in SA, pregnant women are not screened for HBV in 
the public sector. This places the neonates of HBV­infected mothers 
at risk of acquiring HBV infection, as HBV vaccination is only 
started at 6 weeks of age. HIV­infected pregnant women are now 
treated for both HBV and HIV according to the new prevention 
of mother­to­child transmission (PMTCT) guidelines initiated in 
April 2013, which offer tenofovir, lamivudine (or amtricitabine) 
and efavirenz as the first line of treatment regardless of CD4 count. 
Tenofovir, amtricitabine and lamivudine have activity against HBV 
and HIV, thereby reducing the chances of vertical transmission of 
both viruses.[12,22]
Interestingly, the prevalence of HBeAg in this study was 
comparable in the HIV­infected (30.0%) and uninfected (37.5%) 
groups (p=0.7400) (Table 3). This finding indicates that without 
HBV treatment in pregnancy, or immunoprophylaxis to the exposed 
babies, both HIV­infected and HIV­uninfected mothers would be at 
the same risk of transmitting the virus to their neonates. However, 
HIV­infected mothers receive treatment for HBV during pregnancy, 
as highlighted above. It is therefore now the HIV­uninfected mothers 
who are at a much higher risk of transmitting HBV to their babies. 
Without antenatal screening, these HBV­exposed babies would not 
be identified for post­exposure prophylaxis with HBV vaccine and 
immunoglobulins. 
Omitting the birth dose of HBV vaccine results in an increased 
risk of HBV transmission to the neonate if the mother is HBsAg­
positive.[23] The HBV vaccine is 70 ­ 95% effective in preventing 
perinatal infection when administered alone within 24 hours of birth. 
HBV immunoglobulins provide passive immunisation to infants 
born to HBsAg­positive women. Administering the HBV vaccine in 
combination with one dose of hepatitis B immunoglobulin within 24 
hours of birth provides 85 ­ 95% efficacy in preventing perinatal HBV 
infection.[23,24] One study showed that the risk of HBV infection for 
infants born to HBsAg­positive mothers increased significantly when 
the first dose of hepatitis B vaccine was received after 7 days (odds 
ratio 8.6) compared with those vaccinated on days 1 ­ 3 after birth.[8] 
The SA Expanded Programme on Immunisation (EPI) initiates HBV 
vaccination only at 6 weeks of life. Sub­Saharan African studies have 
shown a 10 ­ 20% breakthrough HBV infection rate in those who 
receive a 6­week dose compared with the birth­dose vaccination.[3,8] 
The practice of universal antenatal HBV screening ensures 
that all women with HBV infection receive optimal medical care 
through HBV treatment, regardless of their HIV status, and that 
their neonates receive the appropriate post­exposure prophylaxis. 
However, in developing countries, antenatal screening may be costly 
and not feasible.[25] Some countries with an intermediate or low 
prevalence of chronic HBV infection or limited resources reduce 
costs by not screening pregnant women, but recommend starting 
HBV vaccination from birth without HBV immunoglobulins. This 
strategy is cost­saving but is of moderate efficacy compared with the 
high efficacy and higher cost of maternal screening plus passive and 
active immunisation of neonates.[9] A strategy of administering HBV 
vaccine at birth would be applicable in the SA setting, as there is no 
antenatal screening in the public sector. 
A study published by Guidozzi et al.[26] in 1993, which found 
a low HBeAg prevalence of 4.6% in HBsAg­positive pregnant 
women, concluded that it would not be cost­effective to screen 
for HBV in pregnant urban SA women. However, this study may 
have underestimated the prevalence of HBV and HBeAg as it was 
conducted in predominantly white and urban­born black women, 
who are known to have low prevalence of HBV. The proportion of 
rural­born women, known to have a high prevalence of HBV,[4] was 
estimated at 10% in Guidozzi et al.’s study. 
Our study has shown a high HBeAg prevalence of 30.0% and 37.5% 
in HIV­uninfected and infected individuals, respectively. Although 
the study was conducted in an urban setting, we do not know the 
birth origins of the study participants owing to the retrospective 
nature of this study. However, Gauteng is known to attract people 
from rural areas of SA to seek job opportunities. The current National 
Health Laboratory Service price for HBsAg is ZAR161.10. Screening 
for HBsAg in our cohort would therefore have cost the government 
ZAR381 484.80 to identify 18 HBV­infected patients. This amount 
could be spent on getting more than 69 000 doses of HBV vaccine, 
as the government used to buy the multidose HBV vaccine (with 10 
doses) at ZAR54.93 (excluding tax) from the Biovac company before 
the introduction of hexavalent vaccine (containing HBV vaccine) 
at 6, 10 and 14 weeks (personal communication, Biovac staff, sales 
department, 20 November 2015). We therefore agree with Guidozzi et 
al.’s conclusion that it would not be cost­effective to screen for HBV 
in pregnant urban SA women. The HBV vaccine birth dose without 
immunoglobulins has an efficacy of at least 70% in preventing HBV 
infection.[23,24] Therefore, in the absence of HBV screening in the SA 
public sector, HBV vaccine alone given at birth as part of EPI would 
prevent at least 70% of infections in neonates. 
Giving a birth dose of HBV vaccine to all neonates would serve 
as post­exposure prophylaxis to those exposed to HBV during 
pregnancy, while also fulfilling the role of pre­exposure prophylaxis 
for all neonates. Our data support the recommendation made by 
Spearman and Sonderup[27] that SA should implement a four­dose 
HBV vaccination schedule with just the addition of the birth­dose 
vaccine within 24 hours of delivery. This schedule would be slightly 
more costly but easier to implement as it does not disrupt the 
current HBV vaccination schedule.[27] A three­dose HBV vaccination 
schedule has also been proven to be effective in other parts of the 
world.[25]
Study limitations
The limitations of this study include a small sample size and the 
absence of HBV viral load. We were also not able to trace the records 
of babies born to HBsAg­positive mothers to determine whether they 
received post­exposure prophylaxis and their HBV status. 
Conclusion
This study showed a significantly higher HBV prevalence in HIV­
infected as opposed to HIV­uninfected women. The comparable 
HBeAg prevalence between the two groups indicates that both 
groups were at an increased risk of vertical transmission, therefore 
demonstrating a need for antenatal screening for HBV. Since antenatal 
HBV screening is often not affordable in low­income countries, there 
is a high demand for a birth dose of HBV vaccine for prevention 
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of vertical transmission to the neonates. We therefore recommend 
that the SA National Department of Health review its current HBV 
vaccination schedule to include a birth dose of HBV vaccine to 
cater for neonates exposed to HBV during pregnancy, particularly 
those born to HIV­uninfected women and to HBV­HIV co­infected 
mothers who neither booked for antenatal care nor received PMTCT 
late in pregnancy.
References
1. Espoti SD, Shah D. Hepatitis B in pregnancy: Challenges and treatment. Gastroentrerol Clin North Am 
2011;40(2):355­372. [http://dx.doi.org/10.1016/j.gtc.2011.03.005]
2. Ott JJ, Stevens GA, Groegerb J, Wiersma ST. Global epidemiology of hepatitis B virus infection: New 
estimates of age­specific HBsAg seroprevalence and endemicity. Vaccine 2012;30(12):2212­2219. 
[http://dx.doi.org/10.1016/j.vaccine.2011.12.116]
3. Burnett RJ, Kramvis A, Dochez C, Meheus A. An update after 16 years of hepatitis B vaccination in 
South Africa. Vaccine 2012;30(Suppl 3):C45­C51. [http://dx.doi.org/10.1016/j.vaccine.2012.02.021]
4. Kew MC. Hepatitis B virus infection: The burden of disease in South Africa. S Afr J Epidemiol Infect 
2008;23(1):4­8.
5. Robson SC, Kirsch RE. National strategy for viral hepatitis: Recommendations and guidelines for 
management in South Africa. S Afr Med J 1991;80(4):347­358.
6. Vardas E, Mathai M, Blaauw D, McAnerney J, Coppin A, Sim J. Preimmunization epidemiology of 
hepatitis B virus infection in South African children. J Med Virol 1999;58(2):111­115. [http://dx.doi.
org/10.1002/(SICI)1096­9071(199906)58:2<111::AID­JMV2>3.0.CO;2­B]
7. Sangare L, Sombie R, Combassere AW, et al. Antenatal transmission of hepatitis B virus in an area of 
HIV moderate prevalence, Burkina Faso. Bull Soc Pathol Exot 2009;102(4):226­229.
8. Howell J, Lemoine M, Thursz M. Prevention of materno­foetal transmission of hepatitis B in sub­
Saharan Africa: The evidence, current practice and future challenges. J Viral Hepat 2014;21(6):381­
396. [http://dx.doi.org/10.1111/jvh.12263]
9. Chang M­h. Hepatitis B virus infection. Semin Fetal Neonatal Med 2007;12(3):160­167. [http://dx.doi.
org/10.1016/j.siny.2007.01.013]
10. Ocama P, Opio CK, Lee WM. Hepatitis B virus infection: Current status. Am J Med 2005;118(12):1413.
e15­1413.e22. [http://dx.doi.org/10.1016/j.amjmed.2005.06.021]
11. MacLean B, Hess R. Seroprevalance of hepatitis B surface antigen among pregnant women attending 
the Hospital for Women and Children in Koutiala, Mali. S Afr Med J 2012;102(1):47­49.
12. Ho V, Ho W. Hepatitis B in pregnancy: Specific issues and considerations. J Antivir Antiretrovir 
2012;4(1):3. [http://dx.doi.org/10.4172/jaa.1000046] 
13. Jonas MM. Hepatitis B and pregnancy: An underestimated issue. Liver International 2009;29(suppl 
1):133­139. [http://dx.doi.org/10.1111/j.1478­3231.2008.01933.x]
14. Shi Z, Li X, Ma L, Yang Y. Hepatitis B immunoglobulin injection pregnancy to interrupt hepatitis B 
virus mother­to­child transmission: A meta­analysis. Int J Infect Dis 2010;14(7):e622­e634. [http://
dx.doi.org/10.1016/j.ijid.2009.09.008]
15. World Health Organization. Hepatitis B. Fact sheet No. 204. July 2012. http://www.who.int/
mediacentre/factsheets/fs204/en/ (accessed 3 September 2014).
16. Thio C. Hepatitis B virus infection in HIV­infected persons. Curr Hepatol Rep 2004;3(1):91­97. [http://
dx.doi.org/10.1007/s11901­004­0015­8]
17. Mayaphi SH, Rossouw TM, Masemola DP, Olorunju SA, Mphahlele MJ, Martin DJ. HBV/HIV co­
infection: The dynamics of HBV in South African patients with AIDS. S Afr Med J 2012;102(3):157­162.
18. Andersson MI, Maponga TG, Ijaz S, Theron G, Preiser W, Tedder RS. High HBV viral loads in HIV­
infected pregnant women at a tertiary hospital. J Acquir Immune Defic Syndr 2012;60(1):4. [http://
dx.doi.org/10.1097/QAI.0b013e31825aeee7]
19. National Department of Health, South Africa. The 2012 National Antenatal Sentinel HIV & Herpes 
Simplex Type­2 Prevalence Survey. Pretoria: NDoH. www.doh.gov.za (accessed 16 September 2014). 
20. Thumbiran NV, Moodley D, Parboosing R, Moodley P. Hepatitis B and HIV co­infection in pregnant 
women: Indication for routine antenatal hepatitis B virus screening in a high HIV prevalence setting. 
S Afr Med J 2014;104(4):307­309. [http://dx.doi.org/10.7196/SAMJ.7299]
21. Ahmed SD, Cuevas LE, Brabin BJ, et al. Seroprevalence of hepatitis B and C and HIV in Malawian 
pregnant women. J Infect 1998;37(3):248­251. [http://dx.doi.org/10.1016/S0163­4453(98)91983­1]
22. Chen HL, Lee CN, Chang CH, et al. Efficacy of maternal tenofovir disoproxil fumarate in interrupting 
mother­to­infant transmission of hepatitis B virus. Hepatology 2015;62(2):375­386. [http://dx.doi.
org/10.1002/hep.27837]
23. World Health Organization. Hepatitis B vaccines. Wkly Epidemiol Rec 2009;40(84):405­420. http://
www.who.int/wer/2009/wer8440.pdf (accessed 13 April 2015).
24. Centers for Disease Control and Prevention. Hepatitis B. http://www.cdc.gov/vaccines/pubs/
pinkbook/hepb.html (accessed 28 March 2015).
25. Van Herck K, van Damme P. Benefits of early hepatitis B immunization programs for newborns and 
infants. Pediatr Infect Dis J 2008;27(10):861­869. [http://dx.doi.org/10.1097/INF.0b013e318173966f]
26. Guidozzi F, Schoub BD, Johnson S, Song E. Should pregnant urban South African women be screened 
for hepatitis B? S Afr Med J 1993;83(2):103­105.
27. Spearman CWN, Sonderup MW. Preventing hepatitis B and hepatocellular carcinoma in South 
Africa: The case for a birth­dose vaccine. S Afr Med J 2014;104(9):610­612. [http://dx.doi.org/10.7196/
SAMJ.8607]
Accepted 21 September 2015. 
